Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
3/14 at 7 p.m.) Problems playing video
Glucagon-like peptide-1 medicines and cancer
Closing this gap is a shared responsibility
(2021), Lancet 397(10286), PubMed 33894838 Statistics from preclinical literature Cagrilintide (development code AM833 ), a long-acting amylin analogue , 32 amino acids, molecular weight 3.795 kDa Developed at Novo Nordisk (Denmark) as part of the CagriSema combination program (cagrilintide + semaglutide) Target: amylin receptors (AMY1, AMY2, AMY3) + secondarily the calcitonin receptor , extended half-life via a C16 fatty acid linker Standard dose in clinical trials: 0.164.5 mg/week subcutaneously (Phase 1b/2) Phase 2 (Enebo 2021, n=96): 17.1 % reduction in body weight with CagriSema 2.4 mg + 2.4 mg over 20 weeks vs 9.8 % with semaglutide alone REDEFINE 1 Phase 3 (2024, preliminary data): 22.7 % weight reduction with CagriSema 2.4 mg/2.4 mg over 68 weeks Status: Phase 3 completed 20242025 , FDA filing expected 20252026 Approximately 25+ peer-reviewed publications in PubMed (20182024) Reference sources (PubMed) Enebo LB
It cycles between two states: Reduced (GSH): Ready to work
US$ 29.72
US$ 23.82
US$ 28.80
US$ 28.35
US$ 25.07
US$ 23.75
US$ 26.84
US$ 21.64
US$ 24.05
US$ 22.24
